Enliven Therapeutics Stock Today
| ELVN Stock | 22.33 0.74 3.21% |
Performance2 of 100
| Odds Of DistressOver 56
|
Enliven Therapeutics is selling at 22.33 as of the 13th of September 2024; that is 3.21% down since the beginning of the trading day. The stock's open price was 23.07. Enliven Therapeutics has over 56 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Enliven Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of September 2023 and ending today, the 13th of September 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of March 2020 | Category Healthcare | Classification Health Care |
Enliven Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 47.24 M outstanding shares of which 5.35 M shares are currently shorted by private and institutional investors with about 23.29 trading days to cover. More on Enliven Therapeutics
Moving together with Enliven Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Enliven Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO, CoFounder | Samuel MBA | ||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, Pharmaceutical Products, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsEnliven Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Enliven Therapeutics' financial leverage. It provides some insight into what part of Enliven Therapeutics' total assets is financed by creditors.
| |||||
Enliven Therapeutics (ELVN) is traded on NASDAQ Exchange in USA. It is located in 6200 Lookout Road, Boulder, CO, United States, 80301 and employs 52 people. Enliven Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.09 B. Enliven Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 47.24 M outstanding shares of which 5.35 M shares are currently shorted by private and institutional investors with about 23.29 trading days to cover.
Enliven Therapeutics generates negative cash flow from operations
Check Enliven Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Enliven Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Enliven Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Enliven Therapeutics. Please pay attention to any change in the institutional holdings of Enliven Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Enliven Ownership Details
Enliven Therapeutics Historical Income Statement
Enliven Stock Against Markets
Enliven Therapeutics Corporate Executives
Elected by the shareholders, the Enliven Therapeutics' board of directors comprises two types of representatives: Enliven Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enliven. The board's role is to monitor Enliven Therapeutics' management team and ensure that shareholders' interests are well served. Enliven Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enliven Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Lyssikatos | CoFounder Officer | Profile | |
| Benjamin Hohl | CFO Development | Profile | |
| Anish PharmD | CoFounder COO | Profile |
Additional Information and Resources on Investing in Enliven Stock
When determining whether Enliven Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enliven Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enliven Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enliven Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enliven Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Return On Assets (0.20) | Return On Equity (0.28) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.